2023
Encapsulation of an Antioxidant in Redox-Sensitive Self-Assembled Albumin Nanoparticles for the Treatment of Hepatitis
Yasuda K, Maeda H, Kinoshita R, Minayoshi Y, Mizuta Y, Nakamura Y, Imoto S, Nishi K, Yamasaki K, Sakuragi M, Nakamura T, Ikeda-Imafuku M, Iwao Y, Ishima Y, Ishida T, Iwakiri Y, Otagiri M, Watanabe H, Maruyama T. Encapsulation of an Antioxidant in Redox-Sensitive Self-Assembled Albumin Nanoparticles for the Treatment of Hepatitis. ACS Nano 2023, 17: 16668-16681. PMID: 37579503, DOI: 10.1021/acsnano.3c02877.Peer-Reviewed Original ResearchConceptsAlbumin nanoparticlesRedox characteristicsNanoparticlesStable formReactive oxygen speciesAlbumin moleculeIntramolecular disulfide bondsDisulfide bondsIntermolecular disulfide bridgesDisulfide bridgesPreparationNanoantioxidantsBondsNanostructuresOxygen speciesMoleculesEncapsulationHereinNanoscaleAdditivesAntioxidantsSerum conditionsTreatment of hepatitisWater
2019
Digoxin improves steatohepatitis with differential involvement of liver cell subsets in mice through inhibition of PKM2 transactivation
Zhao P, Han SN, Arumugam S, Yousaf MN, Qin Y, Jiang JX, Torok NJ, Chen Y, Mankash MS, Liu J, Li J, Iwakiri Y, Ouyang X. Digoxin improves steatohepatitis with differential involvement of liver cell subsets in mice through inhibition of PKM2 transactivation. AJP Gastrointestinal And Liver Physiology 2019, 317: g387-g397. PMID: 31411894, PMCID: PMC6842989, DOI: 10.1152/ajpgi.00054.2019.Peer-Reviewed Original ResearchConceptsHigh-fat dietSignificant clinical applicabilityHuman nonalcoholic steatohepatitisNonalcoholic steatohepatitisOral digoxinLiver injuryCell subsetsPathway activationMouse modelHigh-fat diet mouse modelLiver injury mouse modelHepatocyte mitochondrial dysfunctionClinical applicabilityDiet mouse modelInjury mouse modelDifferential involvementLarge clinical experienceNLRP3 inflammasome activationSignificant protective effectHIF-1α transactivationHepatic oxidative stress responseHypoxia-inducible factorLiver inflammationHFD miceWide dosage range
2018
Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions
Minayoshi Y, Maeda H, Yanagisawa H, Hamasaki K, Mizuta Y, Nishida K, Kinoshita R, Enoki Y, Imafuku T, Chuang VTG, Koga T, Fujiwara Y, Takeya M, Sonoda K, Wakayama T, Taguchi K, Ishima Y, Ishida T, Iwakiri Y, Tanaka M, Sasaki Y, Watanabe H, Otagiri M, Maruyama T. Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions. Drug Delivery 2018, 25: 1055-1065. PMID: 29688069, PMCID: PMC6058604, DOI: 10.1080/10717544.2018.1464083.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnti-Inflammatory AgentsB7-H1 AntigenCell LineHepatitisHumansImmunologic FactorsInterferon alpha-2Interferon Type IInterferon-alphaInterleukin 1 Receptor Antagonist ProteinInterleukin-10Kupffer CellsLiverMaleMannoseMiceMice, Inbred C57BLMice, Inbred ICRRAW 264.7 CellsRecombinant ProteinsSerum AlbuminConceptsKupffer cellsImmunomodulatory actionsTypes of hepatitisHepato-protective effectsTreatment of hepatitisAlbumin fusion technologyIL-10Liver injuryPD-L1IL-1raImmunomodulatory effectsModel miceTherapeutic effectivenessSurvival rateIFNα2bRAW264.7 cellsHepatitisInterferon receptorMRNA levelsSignificant inductionConcanavalin AMenMiceConcept studyCells